Evolent Health, Inc. — FY2022 Form 10-K
Reporting period: Fiscal year ended December 31, 2022. This is an annual report, not a standalone quarterly filing; selected fourth-quarter results are included below. Evolent provides value-based-care clinical and administrative services through its Clinical Solutions and Evolent Health Services (EHS) segments.
Financial performance
| Metric | FY2022 | FY2021 | Change / context |
|---|---|---|---|
| Revenue | $1,352.0 million | $908.0 million | Up 48.9%; growth reflected $364.8 million from partner additions and expansion and $79.3 million from IPG and Vital Decisions acquisitions. |
| Cost of revenue | $1,035.4 million | $657.6 million | Up 57.5%; 76.6% of revenue versus 72.4%. |
| Gross margin, approximate | 23.4% | 27.6% | Lower, primarily reflecting mix shift toward performance-based products and higher claims costs. |
| SG&A | $269.3 million | $219.5 million | Up 22.7%; 19.9% of revenue versus 24.2%. |
| Operating income (loss) | $3.6 million | $(42.4) million | Improved; operating margin was approximately 0.3% versus (4.7%). |
| Net loss | $(19.2) million | $(37.6) million | Loss per share was $(0.20) versus $(0.44). |
| Adjusted EBITDA | $106.3 million | $66.3 million | Company-defined non-GAAP segment performance measure; verify reconciliation and adjustments. |
| Operating cash flow | $(11.6) million | $38.7 million | Cash use reflected receivables growth, including Cook County balances, among other working-capital movements. |
FY2022 revenue was $407.5 million in EHS and $944.5 million in Clinical Solutions. The company reported a $43.4 million income-tax benefit, principally associated with a valuation-allowance reduction following the IPG acquisition; it also recorded a $46.0 million TRA liability change, a $23.5 million gain from changes in contingent consideration fair value, and a $10.2 million debt-extinguishment loss.
For the fourth quarter of 2022, revenue was $382.4 million and net loss was $11.3 million, compared with revenue of $248.4 million and net loss of $5.6 million in fourth-quarter 2021.
Financial position and liquidity
- At December 31, 2022, cash and cash equivalents were $188.2 million; restricted cash and investments brought the combined total to $215.2 million.
- Current assets were $478.1 million and current liabilities $433.4 million. Current debt was not separately reported in the supplied balance-sheet summary; the reported current ratio is approximately 1.10.
- Long-term debt, net, was $413.0 million. Principal debt outstanding was reported as $421.8 million, including $225.0 million under the secured term and revolving facilities and $196.8 million of convertible notes.
- Goodwill was $722.8 million and net intangible assets were $442.8 million. No goodwill impairment was recorded in 2022, but the EHS valuation was sensitive to revenue and margin assumptions.
- Management stated that year-end cash and cash equivalents were expected to cover working capital and capital expenditure needs for at least the following 12 months. That assessment predates the January 2023 NIA acquisition financing and should be considered in light of the subsequent capital structure.
Material changes and transactions
- IPG was acquired on August 1, 2022, for consideration valued at $461.7 million, comprising $256.5 million cash, 3.7 million shares, and contingent consideration initially valued at $75.0 million. IPG expanded musculoskeletal surgical-management services.
- NIA, focused on radiology, musculoskeletal, physical medicine and genetics, was acquired on January 20, 2023, after year-end. The transaction involved cash consideration, 8.5 million shares and additional Ares debt financing; the filing describes approximately $400 million cash and $265 million debt financing, with final cash consideration subject to adjustment.
- To finance NIA, the company borrowed an additional $240 million term loan and $25 million revolving facility and issued $168 million gross proceeds of Series A convertible preferred stock. The preferred stock has senior dividend and liquidation rights, cash dividends tied to SOFR plus 6%, and conversion and redemption provisions.
- In August 2022, holders exchanged $92.8 million of 2024 notes for 5.4 million Class A shares, generating a $10.2 million loss on extinguishment.
- Bright Health Group announced it would exit its Individual and Family Plans business for 2023, reducing expected EHS revenue and prompting organizational and strategy changes. The company indicated a future strategic emphasis on complex specialty conditions, which represented about 70% of 2022 corporate revenue before NIA.
Outlook, risks and unusual items
- No quantified forward-looking revenue, earnings or cash-flow guidance is provided in the supplied filing text. Management expects longer-term cost ratios to improve, but notes integration-related SG&A growth and uncertainty around service mix and performance.
- Revenue and receivables are concentrated: Cook County represented 22.4% of FY2022 revenue and 42.5% of short-term trade receivables. Bright Health represented 11.3% of short-term trade receivables at year-end; its planned IFP exit may reduce future revenue.
- Performance-based contracts expose Evolent to medical-cost, utilization, claims-development and pricing risk. The $199.7 million claims and performance-based reserve depends on actuarial estimates; the auditor identified it as a critical audit matter.
- Other significant risks include NIA integration and synergy execution, partner renewals and renegotiations, government policy and Medicaid redeterminations, inflation and labor costs, cybersecurity and privacy, and goodwill impairment.
- Floating-rate secured debt and preferred dividends are tied to SOFR. The company estimated that a 1 percentage-point SOFR increase would add approximately $4.9 million in annual interest expense and $1.8 million in annual preferred dividends.
- The 2022 shareholder class-action settlement of $23.5 million was funded entirely by insurance and is resolved; a related derivative action was dismissed in January 2023. The auditor issued unqualified opinions on the financial statements and internal control; IPG was excluded from management’s internal-control assessment for 2022.
Investor verification priorities
- Verify post-acquisition NIA revenue, earnings contribution, integration costs, realized synergies and final purchase-price accounting.
- Track debt balances, SOFR-based interest costs, preferred dividends, covenant headroom and refinancing or redemption terms.
- Assess cash conversion and receivable collection, especially Cook County balances, alongside claims-reserve development and medical-cost trends.
- Monitor the revenue and cash-flow impact of Bright Health’s IFP exit, Medicaid redeterminations and partner contract renewals.
- Review the assumptions supporting goodwill valuations, the $46.0 million TRA liability and the potential dilution from preferred-stock conversion and acquisition shares.